Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Inclusion Criteria

• •Patients with persistent or recurrent epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer
• •* Platinum-resistant (less than 6 months from date of last platinum therapy to date of first evidence of recurrent or persistent disease) disease as measured by any of the following:
• •* Imaging
• •* Physical exam
• •* CA-125 that is twice the upper limit of normal on two occasions with at least one week apart
• •* No patients who have platinum resistant or refractory disease after more than 6 months since prior therapy
• •Criteria for patients on cancer therapy (e.g., chemotherapy, non-cytotoxic regimens, hormone therapy, or radiation therapy) include recurrent or persistent disease defined as having measurable disease per RECIST (Version 1.1)
• •* Patients not on chemotherapy are also eligible and are not required to have RECIST criteria
• •Life expectancy of at least 6 months
• •Patients with any performance status, yet with the ability to verbally consent and participate in the first assessment
• •* Study measures will be administered in the office/clinic setting, or for study participants who are unable to attend clinics, via telephone or mail (telephone is the preferred back-up means)
• •Patients may have or have had a prior non-gynecologic malignancy within 5 years prior to study enrollment; however, they must have completed all treatments for the disease and have no evidence of disease at the time of enrollment, and ovarian, peritoneal, or fallopian tube cancer must be the primary life-threatening diagnosis
• •Patient must be able to read and write English
• •No patients receiving chemotherapy for platinum-sensitive ovarian cancer, peritoneal, or fallopian tube cancer